NCT06267703Active, not recruiting
Multi-omics Analyses on Etiology and Early Detection of Stomach Cancer Precursor Lesions
Multi-omics Approach for Identification of Etiopathogenesis and Early Detection Biomarkers of Stomach Cancer Precursor Lesions
Source: ClinicalTrials.gov · Last updated 21 Feb 2024
Brief summary (registry, in English)
The overall aim is to utilize multi-omics approach to identify novel etiopathogenesis and early detection biomarkers for stomach cancer precursor lesions. To achieve this aim, first the investigators will use stored serum samples to perform metabolomics profiling among 12,599 twin subjects, among whom 1034 were deemed to have chronic atrophic gastritis based on measured pepsinogen I and II levels. Logistic regression will be used to search for metabolites related to the risk of chronic atrophic gastritis. Second, the investigators will further measure serum proteome by using two quantitatively precise proteomics assays, among the above-mentioned twin subjects. Identified protein biomarkers will be combined with metabolomics biomarkers to create a prediction model for chronic atrophic gastritis. The results will hopefully improve our understanding of the etiological factors and provide promising early detection biomarkers for stomach cancer precursor lesions.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 12599 (actual)
- First submitted
- 12 Feb 2024
- Start date
- Jan 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Karolinska Institutet
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06267703
What you commit to
- Study type: Observational
- Participants enrolled: 12599
- From Jan 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion Criteria:
- participants from the Screening Across the Lifespan (SALT) study within Swedish Twin Registry (STR) who responded to a questionnaire on common diseases and provide a blood sample;
- both twins in the pair had to be alive and living in Sweden;
- had been enrolled in other STR DNA sampling projects;
- Exclusion Criteria:
- previously declined participation in future studies;
- whose blood samples were unavailable or didn't pass initial lab-based QC;
- whose samples were unable to link to the available environmental data.
Age in the registry: 46 years to 97 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska Institutet Coordinator of this site? Confirm its status | Solna | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.